Nyrada Doses First Patient in Phase 2a Trial of Heart Attack Drug Candidate

MT Newswires Live

Jul 06

Nyrada (ASX:NYR) has initiated its PROTECT-MI phase 2a clinical trial with the dosing of the first patient evaluating its transient receptor potential canonical ion channel inhibitor Xolatryp, according to a Monday filing with the Australian bourse.

The trial is a randomized, double-blind, placebo-controlled study that will follow patients for 30 days to assess safety, tolerability, and efficacy outcomes while keeping treatment allocation concealed, per the filing.

The company said that trial site activation is progressing, with Sir Charles Gairdner Hospital in Perth expected to begin recruitment soon, additional Australian sites moving through regulatory approval, and expansion into New Zealand underway, the filing said.

The company expects the last patient to be dosed in mid-2027, with top-line results anticipated about three months after that patient completes a 30-day follow-up visit, the filing added.

The company's shares fell 2% in recent Monday trade.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/2649058614"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2649058614\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2649058614?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-06 09:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2649058614","market":"us","top_or_hot":-1,"title":"Nyrada Doses First Patient in Phase 2a Trial of Heart Attack Drug Candidate","media":"MT Newswires Live","content":"<html><body><p> Nyrada (ASX:NYR) has initiated its PROTECT-MI phase 2a clinical trial with the dosing of the first patient evaluating its transient receptor potential canonical ion channel inhibitor Xolatryp, according to a Monday filing with the Australian bourse.</p><p>The trial is a randomized, double-blind, placebo-controlled study that will follow patients for 30 days to assess safety, tolerability, and efficacy outcomes while keeping treatment allocation concealed, per the filing.</p><p>The company said that trial site activation is progressing, with Sir Charles Gairdner Hospital in Perth expected to begin recruitment soon, additional Australian sites moving through regulatory approval, and expansion into New Zealand underway, the filing said.</p><p>The company expects the last patient to be dosed in mid-2027, with top-line results anticipated about three months after that patient completes a 30-day follow-up visit, the filing added.</p><p>The company's shares fell 2% in recent Monday trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nyrada Doses First Patient in Phase 2a Trial of Heart Attack Drug Candidate</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNyrada Doses First Patient in Phase 2a Trial of Heart Attack Drug Candidate\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-07-06 09:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Nyrada (ASX:NYR) has initiated its PROTECT-MI phase 2a clinical trial with the dosing of the first patient evaluating its transient receptor potential canonical ion channel inhibitor Xolatryp, according to a Monday filing with the Australian bourse.</p><p>The trial is a randomized, double-blind, placebo-controlled study that will follow patients for 30 days to assess safety, tolerability, and efficacy outcomes while keeping treatment allocation concealed, per the filing.</p><p>The company said that trial site activation is progressing, with Sir Charles Gairdner Hospital in Perth expected to begin recruitment soon, additional Australian sites moving through regulatory approval, and expansion into New Zealand underway, the filing said.</p><p>The company expects the last patient to be dosed in mid-2027, with top-line results anticipated about three months after that patient completes a 30-day follow-up visit, the filing added.</p><p>The company's shares fell 2% in recent Monday trade.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7096","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2649058614","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2649058614","pubTimestamp":1783299790,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Nyrada  has initiated its PROTECT-MI phase 2a clinical trial with the dosing of the first patient evaluating its transient receptor potential canonical ion channel inhibitor Xolatryp, according to a Monday filing with the Australian bourse.The trial is a randomized, double-blind, placebo-controlled study that will follow patients for 30 days to assess safety, tolerability, and efficacy outcomes while keeping treatment allocation concealed, per the filing.The company said that trial site activation is progressing, with Sir Charles Gairdner Hospital in Perth expected to begin recruitment soon, additional Australian sites moving through regulatory approval, and expansion into New Zealand underway, the filing said.The company expects the last patient to be dosed in mid-2027, with top-line results anticipated about three months after that patient completes a 30-day follow-up visit, the filing added.The company's shares fell 2% in recent Monday trade.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7096":"制药","NYR.AU":"NYRADA INC-CDI"},"translate_title":"Nyrada在心脏病候选药物2a期试验中为首例患者给药","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NYR.AU":1},"content_text":"Nyrada (ASX:NYR) has initiated its PROTECT-MI phase 2a clinical trial with the dosing of the first patient evaluating its transient receptor potential canonical ion channel inhibitor Xolatryp, according to a Monday filing with the Australian bourse.The trial is a randomized, double-blind, placebo-controlled study that will follow patients for 30 days to assess safety, tolerability, and efficacy outcomes while keeping treatment allocation concealed, per the filing.The company said that trial site activation is progressing, with Sir Charles Gairdner Hospital in Perth expected to begin recruitment soon, additional Australian sites moving through regulatory approval, and expansion into New Zealand underway, the filing said.The company expects the last patient to be dosed in mid-2027, with top-line results anticipated about three months after that patient completes a 30-day follow-up visit, the filing added.The company's shares fell 2% in recent Monday trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}